Please login to the form below

Not currently logged in
Email:
Password:

SGLT2 inhibitors

This page shows the latest SGLT2 inhibitors news and features for those working in and with pharma, biotech and healthcare.

AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients

AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients

SGLT2 inhibitor failed to significantly reduce the number of patients who experienced organ failure or died compared to placebo. ... SGLT2 inhibitors – such as Farxiga (dapagliflozin) – can be used to provide organ protection for patients with

Latest news

More from news
Approximately 5 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    The introduction of a wave of SGLT2 inhibitors will further energise the market - with Novo Nordisk, J&J, Lily, Boehringer, AZ, Merck and Pfizer all due to compete in this space.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    the way SGLT2 inhibitors work by reducing the amount of glucose absorbed in the kidney and passing it out through urine. ... Forxiga is set to face competition from other SGLT2 inhibitors either recently approved or on the horizon, including

  • Pharma deals during April 2013 Pharma deals during April 2013

    The partnership is to co-develop and commercialise Pfizer's phase III ready oral sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin for the treatment of type 2 diabetes, both as a ... SGLT2 inhibitors block the reabsorption of glucose by the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....